Inflammation

C4X Discovery receives Sanofi milestone payment

Retrieved on: 
Wednesday, July 6, 2022 - 8:29am

MANCHESTER, United Kingdom, July 06, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that it has received a milestone payment of €3 million from Sanofi under the IL-17A Inhibitor programme license agreement entered into in April 2021.

Key Points: 
  • C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients.
  • We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders.
  • Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.
  • Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

Nuvation Bio, Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Tuesday, July 5, 2022 - 8:26pm

​LOS ANGELES, July 05, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nuvation Bio Inc. (“Nuvation” or “the Company”) (NYSE: NUVB) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Nuvation investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, July 05, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors.
  • Nuvation investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

CBD Move Free Partners with Novvi LLC, Market Leader in Sustainable, Biodegradable Ingredients for Personal Care

Retrieved on: 
Tuesday, July 5, 2022 - 5:47pm

BELLEVUE, Wash., July 5, 2022 /PRNewswire/ -- CBD Move Free today announced a strategic partnership with Novvi, a leader in creating breakthrough plant-derived petroleum alternative materials for better living that emphasize performance while maintaining a low carbon footprint. Through the partnership, CBD Move Free will deliver the first-ever line of Cannabidiol (CBD) relief products using Novvi's responsibly sourced, plant-derived ingredients, including its ultra-moisturizing Luxtra emollients.

Key Points: 
  • Through the partnership, CBD Move Free will deliver the first-ever line of Cannabidiol (CBD) relief products using Novvi's responsibly sourced, plant-derived ingredients, including its ultra-moisturizing Luxtra emollients.
  • "It was a natural fit to partner with Novvi, who is truly at the forefront of enabling the development of high-performance personal care products that utilize the most sustainable and leading-edge ingredients available."
  • CBD Move Free is the dba of JPS Products, Inc. JPS Products, Inc. also operates the brands Hemp Move Free and JPS Move Free.
  • Novvi is the industry leader in naturally derived synthetic ingredients for beauty and personal care.

AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism

Retrieved on: 
Tuesday, July 5, 2022 - 4:00pm

The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI.

Key Points: 
  • The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI.
  • The 1000 U/Kg dose tested in this study is, comparable to the dose currently being tested in the global phase III pivotal study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury (SA-AKI).
  • We are very encouraged by the findings of this study, as these data further validate the role of ilofotase alfa in protecting the kidney during episodes of acute kidney injury, said Maarten Kraan, MD, PhD, Chief Medical Officer of AM-Pharma.
  • Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year.

Old Man, 75 - Rejuvenates His Telomeres to the Equivalent of a 10-Year-Old — Extended Longevity Demonstrates Conclusive Proof

Retrieved on: 
Tuesday, July 5, 2022 - 3:11pm

Telomeres are the end caps of chromosomes and protect them from unraveling, much like the plastic tip of a shoelace.

Key Points: 
  • Telomeres are the end caps of chromosomes and protect them from unraveling, much like the plastic tip of a shoelace.
  • Each time the cell divides the telomeres gets shorter until it is no longer capable of dividing.
  • Available on the Extended Longevity website are case studies detailing before and after results of a small test cohort.
  • Additionally, the Company has launched a crowdfunding offering on Wefunder , with perks that reward the investor with sets of the Extended Longevity Protocol.

ORION BIOTECHNOLOGY ADDS GPCR EXPERT TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
Tuesday, July 5, 2022 - 3:03pm

Ottawa, Canada, July 05, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company targeting previously-undruggable G Protein-Coupled Receptors (GPCRs), today announced that Dr. Antal Rot, a world-renowned expert in the role of chemokines in inflammation, has joined Orions scientific advisory board (SAB).

Key Points: 
  • Ottawa, Canada, July 05, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company targeting previously-undruggable G Protein-Coupled Receptors (GPCRs), today announced that Dr. Antal Rot, a world-renowned expert in the role of chemokines in inflammation, has joined Orions scientific advisory board (SAB).
  • at the Semmelweis University in Budapest, Hungary before completing his post-doctoral research training at the National Cancer Institute (Frederick, USA) in the lab of Edward Leonard.
  • Orion Biotechnology Canada Ltd. is unlocking the therapeutic potential of previously-undruggable G Protein-Coupled Receptors (GPCRs).
  • With its team of world-renowned experts in GPCR pharmacology and peptide/protein engineering, Orion Biotechnology is well-positioned to improve patient outcomes.

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, July 5, 2022 - 12:00pm

WATERTOWN, Mass., July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Richard Nieman, MD, has been appointed Chief Medical Officer, effective July 11, 2022. Dr. Nieman brings more than 25 years of experience in drug development and medical affairs, with a proven track record in developing medicines through commercialization and beyond.

Key Points: 
  • (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Richard Nieman, MD, has been appointed Chief Medical Officer, effective July 11, 2022.
  • "We're pleased to welcome Dr. Nieman as our Chief Medical Officer," said Maria Palasis, PhD, CEO of Lyra Therapeutics.
  • "Dr. Nieman joins the Lyra team at a critical time with our lead candidate LYR-210 in pivotal Phase 3 trials.
  • Nieman assumes the role of Chief Medical Officer previously held by Dr. Robert Kern, who will continue to work closely with the Company in the role of Chief Clinical Advisor.

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Retrieved on: 
Tuesday, July 5, 2022 - 12:00pm

(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced participation at the William Blair Biotech Focus Conference 2022 (the Conference).

Key Points: 
  • (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced participation at the William Blair Biotech Focus Conference 2022 (the Conference).
  • Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will take part in a fireside chat during the conference.
  • The Conference will be held at The St. Regis New York hotel from July 12-13, during which Lyra will also host one-on-one meetings with investors.
  • Lyra Therapeutics, Inc.is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

Retrieved on: 
Tuesday, July 5, 2022 - 8:30am

Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialization.

Key Points: 
  • Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialization.
  • Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.
  • The parties would share both funding for the discovery and development of the programs and financials resulting from the commercialization of any eventual drug candidates.
  • In the two decades of working with Pharma, Biotech and Academic partners, Aurigene has contributed to delivering 16 small molecule and peptide drug candidates, currently in clinical development.

Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770

Retrieved on: 
Tuesday, July 5, 2022 - 6:30am

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of two preclinical articles on X-Linked Adrenoleukodystrophy (ALD) for PXL065 and PXL770.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of two preclinical articles on X-Linked Adrenoleukodystrophy (ALD) for PXL065 and PXL770.
  • An article on PXL065 has been published in The Journal of Inherited Metabolic Disease (JIMD) and is entitled Therapeutic potential of deuterium-stabilized (R)-pioglitazone - PXL065 - for X-linked adrenoleukodystrophy.
  • These publications describe similar beneficial preclinical profiles of PXL770 and PXL065 in models of ALD.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.